Cite
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
MLA
E. Eigendorff, et al. “Expression of the CTLA-4 Ligand CD86 on Plasmacytoid Dendritic Cells (PDC) Predicts Risk of Disease Recurrence after Treatment Discontinuation in CML.” Leukemia, vol. 32, no. 4, Jan. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....beddfa6becb05a7c039ad92cc111fc2f&authtype=sso&custid=ns315887.
APA
E. Eigendorff, Christian Dietz, Cornelius F. Waller, G. Freunek, Martin C. Müller, Thomas Illmer, Mahon Fx, Andreas Neubauer, Florian Finkernagel, T H Brümmendorf, Joelle Guilhot, Stefan Hanzel, Rüdiger Hehlmann, Cornelia Brendel, Sabrina Inselmann, Magdalena Huber, S K Metzelder, Jolanta Dengler, Andreas Burchert, … Christin Schütz. (2018). Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia, 32(4).
Chicago
E. Eigendorff, Christian Dietz, Cornelius F. Waller, G. Freunek, Martin C. Müller, Thomas Illmer, Mahon Fx, et al. 2018. “Expression of the CTLA-4 Ligand CD86 on Plasmacytoid Dendritic Cells (PDC) Predicts Risk of Disease Recurrence after Treatment Discontinuation in CML.” Leukemia 32 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....beddfa6becb05a7c039ad92cc111fc2f&authtype=sso&custid=ns315887.